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Most cancer cells primarily produce their energy through a high rate of glycolysis 
followed by lactic acid fermentation even in the presence of abundant oxygen. This 
phenomenon is called Warburg effect, also known as aerobic glycolysis, was firstly 
reproted by Warburg in 1920s. Pyruvate dehydrogenase kinase (PDK) 1, a kinase which 
inactivates the enzyme pyruvate dehydrogenase (PDH), is commonly overexpressed in 
tumors and recognized as a novel therapeutic target in colon cancer. Suppression of 
PDH by PDK1 prevents the conversion of cytoplasmic pyruvate into acetyl-CoA and 
then cytoplasmic pyruvate is converted into lactate even in the presence of oxygen 
presenting an advatage for cancer growth. Here, we report hemistepsin A, as a novel 
PDK kinase inhibitor, decreases PDK activity by binding to the lipoamide-binding 
domain of PDK1 without affecting its expression. Hemistepsin A is a sesquiterpene 
lactone isolated from Hemistepta lyrata Bunge (Compositae). H. lyrata has been used 
for the treatment of colon disease, such as diarrhea, hemafecia, and anal fistula, in 
traditional medicine of Eastern Asia. We demonstrate that hemistepsin A has anti-
cancer effect on several colorectal cancer cells. After treatment with hemistepsin A, 
lactate production was markedly decreased. In the meantime, intracellular reactive 
oxygen species (ROS) levels and mitochondrial damages were increased. In addition, 
apoptosis was promoted with enhanced activation of caspase-3 and -9, improved 
cleaved PARP, enhanced level of Bax expression, decreased Bcl-2 expression. In in vivo 
mice models inoculated with CT26 colon carcinoma, hemistepsin A effectively 
suppressed tumor growth as determined by the reduction of tumor volume and 
weight, inducing by inhibiting the PDK1 activity but not by its expression. Taken 
together, we suggest that hemistepsin A suppresses growth of colorectal cancer 
through inhibiting activity of PDK1. 
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